Search clinical trials for: Zanubrutinib and RCHOP/RDHAP

Total 345 results

Shanxi Province Cancer Hospital

Not yet recruiting

A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients (Z+RCHOP/RDHAP)

Mantle Cell Lymphoma

China
Sun Yat-sen University

Recruiting

Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Huazhong University of Science and Technology

Recruiting

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

Diffuse Large B Cell Lymphoma

China
Fudan University
Xiangya Hospital of Central South University; Shanghai Changzheng Hospital; Baotou...

Active, not recruiting

A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression

Diffuse Large B-cell Lymphoma(DLBCL)

China
First Affiliated Hospital of Wenzhou Medical University

Recruiting

The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.

Diffuse Large B Cell Lymphoma

China
Sun Yat-sen University

Recruiting

A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

Double Express Diffuse Large B-cell Lymphoma

China
Prof. Dr. M. Dreyling (co-chairman)
LMU Klinikum

Recruiting

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Mantle Cell Lymphoma

Germany, Sweden, Denmark, Italy, Norway
Zhejiang Cancer Hospital

Recruiting

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Diffuse Large B Cell Lymphoma

China
PATH
Tulane University; Ministry of Health, Zambia; Minister of Community Development...

Completed

Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia

Malaria | Malaria, Falciparum

Zambia
Zhang Lei, MD

Recruiting

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Thrombocytopenia | Antiphospholipid Syndrome | Treatment

China
Shandong Provincial Hospital

Recruiting

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

China
Henan Cancer Hospital

Not yet recruiting

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell
Fudan University

Recruiting

ZR-CHOP in DLBCL With Specific Gene Abnormality

Diffuse Large B Cell Lymphoma

China
Xuanwu Hospital, Beijing

Recruiting

An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

Neuromyelitis Optica

China
Zhang Lei

Recruiting

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Immune Thrombocytopenia | Treatment

China
Matthew C. Baker
Stanford University

Recruiting

Zanubrutinib in Patients With IgG4-Related Disease

IgG4 Related Disease

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

Zanubrutinib in Primary Cold Agglutinin Disease (HOVON169CAD)

Lymphoma

Norway, Netherlands, Denmark, Belgium
The First Affiliated Hospital of Soochow University

Recruiting

Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

Untreated Mantle Cell Lymphoma

China
Zhejiang Cancer Hospital

Recruiting

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma

China
Fondazione Italiana Linfomi ONLUS
Janssen Pharmaceutica; Janssen-Cilag Ltd.; Centro di Riferimento per l'Epidemiologia...

Completed

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. (FIL_VERAL12)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-cell Lymphoma Refractory

Italy
Ruijin Hospital
The First Affiliated Hospital of Nanchang University; Qilu Hospital of Shandong... and other collaborators

Recruiting

The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

Diffuse Large B-Cell Lymphoma

China
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan

Terminated

Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)

Non-Hodgkin's Lymphoma

Japan
UMC Utrecht
BeiGene

Not yet recruiting

Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy (MAGNAZ)

Monoclonal Gammopathy of Uncertain Significance

Netherlands
Fudan University

Recruiting

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma | Maintenance Therapy

China
Henan Cancer Hospital

Recruiting

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Central Nervous System Lymphoma

China
Fondazione Italiana Linfomi ONLUS

Recruiting

Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

Non Hodgkin Lymphoma

Italy
Yune Zhao

Unknown

To Compare the Progressive Cracking Technique and Conventional Chop Technique on Corneal Endothelial Cells in Patients With Hard Nucleus Cataract

Hard Nuclear Cataract | Corneal Endothelial Cell | Progressive Cracking Technique

China
Emergent BioSolutions

Terminated

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

T-cell Lymphoma
University Health Network, Toronto

Not yet recruiting

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (ZanTisle)

Large B-cell Lymphoma
Sun Yat-sen University

Recruiting

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL

Mantle Cell Lymphoma | Newly-diagnosed Mantle Cell Lymphoma

China
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Withdrawn

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma (FIL_POLARDHAP)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

Italy
Zhejiang Cancer Hospital

Recruiting

XPO-1 in Combination With RCHOP for DH/TH Lymphoma

Double Hit Lymphoma | Triple Hit Lymphoma

China
Sherief Abd-Elsalam

Recruiting

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

Lymphoma

Egypt
French Innovative Leukemia Organisation
Amgen

Completed

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Richter Syndrome

France
Sun Yat-sen University

Completed

DLBCL Treatment in Children and Adolescents

Diffuse Large B-cell Lymphoma
Ruijin Hospital

Active, not recruiting

Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
London School of Hygiene and Tropical Medicine
Medical Research Council Unit, The Gambia

Terminated

Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia (SAFEPRIM-II)

Malaria

Gambia
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL (ZFCR/ZBR)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Newly Diagnosed

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Refractory/Relapsed Autoimmune Hemolytic Anemia

China
Peking University People's Hospital

Completed

A Study of Zanubrutinib in Patients With ITP

Immune Thrombocytopenia | Bruton Tyrosine Kinase

China
Weill Medical College of Cornell University
Genentech, Inc.; BeiGene

Recruiting

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Leukemia, Lymphocytic, Chronic, B-Cell

United States
The University of Texas Health Science Center at...

Withdrawn

Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy

Lymphoma, B-Cell

United States
Nanjing Yoko Biomedical Co., Ltd.

Recruiting

A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Unspecified Site

China
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
BeiGene

Active, not recruiting

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Japan
The University of Hong Kong

Recruiting

Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET

Subfertility

China
Peking Union Medical College Hospital

Recruiting

Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial (iMCD)

Idiopathic Multicentric Castleman's Disease

China
Fudan University

Completed

Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL

Lymphoma

China

Search clinical trials for: Zanubrutinib and RCHOP/RDHAP

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations